Wadih Arap, Director, Rutgers Cancer Institute of New Jersey
Director of the Cancer Institute of New Jersey and the Chief of Hematology/Oncology. His MD degree is from USP, and his PhD from Stanford University. He trained in Hem/Onc as a fellow at Memorial Sloan-Kettering, postdoctoral at the Burnham Institute. He was the Deputy Director in the Department of Genitourinary Medical Oncology at MD Anderson Cancer Center, where he co-directed an active research and drug development program with Dr. Pasqualini. Given his extensive training as a physician-scientist, he actively treats patients. Earlier in his scientific training, Dr. Arap has worked on understanding the genetic progression of malignant tumors, endothelial cell adhesion, angiogenesis, metastasis, and vascular molecular markers. His current interests include the translation of biotechnology and the molecular diversity of cancer into clinical applications and the development of novel therapeutic and imaging strategies. Drs. Arap and Pasqualini are co-founders of 5 biotechnology companies, including, PhageNova Bio, which are currently advancing multiple technologies and drug candidates towards clinical trials.